|
1
|
Tan P and Yeoh KG: Genetics and molecular
pathogenesis of gastric adenocarcinoma. Gastroenterology.
149:1153–1162.e3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11 (Internet). International Agency
for Research on Cancer Lyon, France: 2013, http://globocan.iarc.fr
|
|
3
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song JH and Meltzer SJ: MicroRNAs in
pathogenesis, diagnosis, and treatment of gastroesophageal cancers.
Gastroenterology. 143:35–47.e2. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song S and Ajani JA: The role of microRNAs
in cancers of the upper gastrointestinal tract. Nat Rev
Gastroenterol Hepatol. 10:109–118. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY and
Yan M: microRNA-21 promotes tumor proliferation and invasion in
gastric cancer by targeting PTEN. Oncol Rep. 27:1019–1026.
2012.PubMed/NCBI
|
|
8
|
Lai KW, Koh KX, Loh M, Tada K, Subramaniam
MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et
al: Singapore Gastric Cancer Consortium: MicroRNA-130b regulates
the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer.
46:1456–1463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varambally S, Cao Q, Mani RS, Shankar S,
Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa
M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, et
al: MicroRNA-375 is downregulated in gastric carcinomas and
regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer
Res. 70:2339–2349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie Y, Song J, Zong Q, Wang A, Yang Y, Liu
F and Meng X: Decreased expression of miR-134 and its clinical
significance in human colorectal cancer. Hepatogastroenterology.
62:615–619. 2015.PubMed/NCBI
|
|
12
|
Bao Y, Peng L, Ma J, Liu K and Li W:
Decreased miR-134 expression and its tumor-suppressive function in
human osteosarcoma. Genet Mol Res. 14:16771–16781. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Ma Y, Wang S, Chen F and Gu Y:
C/EBPα inhibits proliferation of breast cancer cells via a novel
pathway of miR-134/CREB. Int J Clin Exp Pathol. 8:14472–14478.
2015.PubMed/NCBI
|
|
14
|
Haller F, von Heydebreck A, Zhang JD,
Gunawan B, Langer C, Ramadori G, Wiemann S and Sahin O:
Localization- and mutation-dependent microRNA (miRNA) expression
signatures in gastrointestinal stromal tumours (GISTs), with a
cluster of co-expressed miRNAs located at 14q32.31. J Pathol.
220:71–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Snyder CM, Mardones GA, Ladinsky MS and
Howell KE: GMx33 associates with the trans-Golgi matrix in a
dynamic manner and sorts within tubules exiting the Golgi. Mol Biol
Cell. 17:511–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scott KL, Kabbarah O, Liang MC, Ivanova E,
Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, et al:
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in
cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu BS, Hu H, Zhu CY, Gu YL and Li JP:
Overexpression of GOLPH3 is associated with poor clinical outcome
in gastric cancer. Tumour Biol. 34:515–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng J, Fang Y, Tao Y, Li K, Su T, Nong Y,
Xie F and Lai M: Mechanisms of GOLPH3 associated with the
progression of gastric cancer: A preliminary study. PLoS One.
9:e1073622014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dippold HC, Ng MM, Farber-Katz SE, Lee SK,
Kerr ML, Peterman MC, Sim R, Wiharto PA, Galbraith KA, Madhavarapu
S, et al: GOLPH3 bridges phosphatidylinositol-4-phosphate and
actomyosin to stretch and shape the Golgi to promote budding. Cell.
139:337–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Q and Guan KL: Expanding mTOR
signaling. Cell Res. 17:666–681. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu C, Ren C, Han J, Ding Y, Du J, Dai N,
Dai J, Ma H, Hu Z, Shen H, et al: A five-microRNA panel in plasma
was identified as potential biomarker for early detection of
gastric cancer. Br J Cancer. 110:2291–2299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han C, Zhou Y, An Q, Li F, Li D, Zhang X,
Yu Z, Zheng L, Duan Z and Kan Q: MicroRNA-1 (miR-1) inhibits
gastric cancer cell proliferation and migration by targeting MET.
Tumour Biol. 36:6715–6723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Riquelme I, Tapia O, Leal P, Sandoval A,
Varga MG, Letelier P, Buchegger K, Bizama C, Espinoza JA, Peek RM,
et al: miR-101-2, miR-125b-2 and miR-451a act as potential tumor
suppressors in gastric cancer through regulation of the
PI3K/AKT/mTOR pathway. Cell Oncol. 39:23–33. 2016. View Article : Google Scholar
|
|
25
|
Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y,
Yao H, Liu X, Ke Y, Si J, et al: MiR-375 frequently downregulated
in gastric cancer inhibits cell proliferation by targeting JAK2.
Cell Res. 20:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui
J, Liu Y, Gao Z, Li J, Shen L, et al: Combination of hsa-miR-375
and hsa-miR-142-5p as a predictor for recurrence risk in gastric
cancer patients following surgical resection. Ann Oncol.
22:2257–2266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen LG, Wang HJ, Yao HB, Guan TP, Wu F,
He XJ, Ma YY, Tao HQ and Ye ZY: GP73 is down-regulated in gastric
cancer and associated with tumor differentiation. World J Surg
Oncol. 11:1322013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sechi S, Frappaolo A, Belloni G, Colotti G
and Giansanti MG: The multiple cellular functions of the
oncoprotein Golgi phosphoprotein 3. Oncotarget. 6:3493–3506. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Farber-Katz SE, Dippold HC, Buschman MD,
Peterman MC, Xing M, Noakes CJ, Tat J, Ng MM, Rahajeng J, Cowan DM,
et al: DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3.
Cell. 156:413–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hohenberger P and Gretschel S: Gastric
cancer. Lancet. 362:305–315. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murayama T, Inokuchi M, Takagi Y, Yamada
H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between
outcomes and localisation of p-mTOR expression in gastric cancer.
Br J Cancer. 100:782–788. 2009. View Article : Google Scholar : PubMed/NCBI
|
